TissueTech™, Inc is a leader in regenerative human amniotic and umbilical cord tissue-based products for use in the wound care and orthopedic markets.
The Company has pioneered the clinical application of human placental tissues. Since its inception in 1997, more than 200,000 patients have been treated with TissueTech products and the Company’s groundbreaking scientific and clinical achievements have been documented in more than 300 peer-reviewed publications since 1995.
The Company’s first product, AmnioGraft®, is the only tissue graft designated by the Food and Drug Administration (FDA) as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. .
TissueTech was founded in 2001 as a managing entity for Bio-Tissue®, Inc., which had been established in 1997 as the first company to introduce cryopreserved amniotic membrane to the commercial market and address an unmet need for better surgical and therapeutic options for ocular surface conditions. The development process for the Company’s proprietary technology began in 1986 with the award of a National Institute of Health research grant to the Company’s founder, Scheffer C. G. Tseng, MD, PhD. Dr. Tseng has spearheaded efforts in the scientific and clinical community to utilize the innate regenerative properties of human amniotic membrane and umbilical cord to promote wound healing. Since then, the Company has distinguished itself with continued NIH funding to support ongoing research into the regenerative properties of placental tissues and the development of products that transfer these regenerative capabilities into adult wound healing environments.
Bio-Tissue has led the ophthalmic market as the only company able to make claims regarding the ability of its products to modulate inflammation, minimize scarring, prevent angiogenesis and provide analgesic relief for ocular applications. A second commercial entity, Amniox Medical, was founded in 2011 to expand the use of this industry-leading technology in the wound care and orthopedic sectors. In its short history, Amniox has also become a leader in both of these sectors.
The Company continues to receive recognition for its many accomplishments. In 2014, TissueTech was recognized as one of the Inc. 5000 Fastest Growing Private Companies in the United States and as Minority-Owned Business of the Year by the Greater Miami Chamber of Commerce in 2015. The Company was the recipient of the prestigious Tibbetts Award from the United States Small Business Administration in recognition of its significant contributions to the field of regenerative medicine.
- First NIH grant received
- First clinical publication in Cornea
- Bio-Tissue® founded
- Commercialization of AmnioGraft® - first amniotic membrane allograft for clinical use
- First CryoTek® patent issued
- TissueTech™ founded
- Company received FDA designation for wound healing for AmnioGraft
- Company received FDA 510k clearance for PROKERA®
- PROKERA Launched – first amniotic allograft for use without sutures
- Company launches AmnioGuard® - first umbilical cord allograft for clinical use
- Amniox® Medical founded
- Series A funding - $10M
- Series B funding - $15M
- 200,000 applications of the Company’s products